{"id":"W3088611248","doi":"10.1016/j.annonc.2020.08.2296","title":"LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":205,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Internal medicine; Interim analysis; Cancer; Oncology; FOLFOX; Randomized controlled trial; Population; Ipilimumab; Gastroesophageal Junction; Chemotherapy; Gastroenterology; Adenocarcinoma; Oxaliplatin; Immunotherapy; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001098359,0.0006415803,0.001614164,0.0002420137,0.0002014243,0.000891269,0.0006237476,0.0008295639,0.003798129],"category_scores_gemma":[0.001465498,0.000300668,0.003111306,0.0003296825,0.0003246515,0.0006784671,0.0003955769,0.001607427,0.0005390915],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008545003,"about_ca_system_score_gemma":0.0006037339,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00179992,"about_ca_topic_score_gemma":0.005258754,"domain_scores_codex":[0.9995888,0.0001940201,0.00002775265,0.00009185047,0.00003388704,0.00006379923],"domain_scores_gemma":[0.9993576,0.0001861889,0.0001995059,0.00005035917,0.00003251129,0.0001737656],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8970216,0.003524726,0.02216168,0.001984864,0.008390286,0.00006124545,0.00007028417,0.001160615,0.00235818,0.0002307274,0.00266166,0.06037403],"study_design_scores_gemma":[0.59789,0.206461,0.14353,0.0008625076,0.03687776,0.0002924374,0.0002391453,0.002900976,0.002248225,0.000886085,0.007714403,0.00009747386],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9823789,0.01203721,0.0001642749,0.0004979846,0.0002944424,0.0002235249,0.002090875,0.0000398435,0.00227296],"genre_scores_gemma":[0.9911532,0.003357702,0.000417662,0.0007455266,0.0002516806,0.000204595,0.002313538,0.00001365899,0.001542458],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003798129,"threshold_uncertainty_score":0.01270598,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.103485147283131,"score_gpt":0.3842591844838083,"score_spread":0.2807740372006773,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}